Accenture Ventures, a strategic arm of Accenture (NYSE: ACN), recently announced its investment in Turbine, a forward-thinking predictive simulation company dedicated to interpreting human biology. This investment aims to bolster Turbine’s capabilities in providing valuable biological insights to global biopharma…
Genentech, a member of the Roche Group, disclosed favorable outcomes from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist aimed at addressing obesity and type 2 diabetes. The study revealed that administering CT-388 through a once-weekly…
Nutcracker Therapeutics, a biotechnology company focused on developing transformative RNA therapies through its proprietary technology platform, announced the presentation of key prostate cancer antigen research by its partners at the University of California, San Francisco (UCSF). The data, foundational to…
Legend Biotech Corporation (NASDAQ: LEGN), a global pioneer in cell therapy, unveiled its unaudited financial performance for the first quarter of 2024 alongside notable corporate achievements. Dr. Ying Huang, CEO of Legend Biotech, expressed satisfaction with the progress made during…
UCB, a global biopharmaceutical company, announced that the Journal of Neurology has published data from the Phase 3 RAISE study and the ongoing RAISE-XT open-label extension (OLE) study on the long-term effects of zilucoplan on fatigue in adult patients with…
Sanofi, the largest private contributor to France’s health ecosystem security and independence, announced a €1 billion investment to expand bioproduction at its sites in Vitry-sur-Seine, Le Trait, and Lyon Gerland. This initiative will create over 500 jobs, enhancing France’s capacity…
AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals have announced a collaboration and option-to-license agreement aimed at developing next-generation therapies for psychiatric disorders. This partnership combines AbbVie’s psychiatric expertise with Gilgamesh’s innovative research platform to discover novel neuroplastogens. Classic psychedelic compounds offer…
The anticipated growth of the global PEGylated proteins market is significant, with projections indicating a rise from $10.2 billion in 2023 to $15.9 billion by 2028, reflecting a robust compound annual growth rate (CAGR) of 9.4% over the forecast period.…
A clinical-stage biopharmaceutical company, specializing in the advancement and market introduction of seralutinib for the management of pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), has announced the approval of an inducement grant. The Compensation…
A leading performance beauty enterprise, specializing in curating an aesthetic range of consumer brands, has announced the allocation of non-qualified stock options for the acquisition of a combined total of 10,990 shares of Evolus, alongside 42,759 restricted stock units (RSUs)…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) revealed today its plans to showcase pivotal findings from the CAHtalyst™ Adult Phase 3 clinical study, shedding light on baseline characteristics of adults grappling with congenital adrenal hyperplasia (CAH). Additionally, the presentation encompassed insights gleaned…
CVS Health® Survey Highlights Growing Mental Health Concerns A recent survey conducted by CVS Health® (NYSE: CVS) in collaboration with Morning Consult reveals an alarming trend: concerns about mental health are on the rise across the United States. Key findings…